| Reagan-Udall Foundation

Read more about INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old

Read more about Neurobiological Underpinnings of Neuropsychological Consequences in Long COVID

Read more about Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).

Read more about Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

The FDA will increasingly use accelerated approval for gene therapies aimed at rare conditions, according to Peter Marks, the FDA’s top official overseeing cell and gene therapies, the clearest signal yet of how widely the agency will deploy its expedited pathway.

INAVAC Vaccine Phase III (Immunobridging Study) in Healthy Population Aged 12 to 17 Years Old

Neurobiological Underpinnings of Neuropsychological Consequences in Long COVID

Calcifediol in the Treatment of SARS-CoV-2 Disease (COVID-19).

Study to Evaluate the Safety & Immunogenicity of IMNN-101 Administered in Healthy Adults Previously Vaccinated Against SARS-CoV-2

Accelerated approval will be 'the norm' for gene therapies, FDA's Peter Marks says - Endpoints

Post-COVID-19 Chronic Fatigue Syndrome

COVID-19 Booster Study in Healthy Adults in Australia

How biomarkers can support regulatory rare disease pathways - BioNews

Orano Med

RadioMedix

Subscribe for updates from the Reagan-Udall Foundation for the FDA